ClinicalTrials.gg
TerminatedNCT02384954Updated Jul 3, 2024Results posted

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

A Phase 1/2 interventional study of Rituximab and N-803 in Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma, sponsored by Altor BioScience. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.

Primary conditionLymphoma, Non-HodgkinRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Non-Hodgkin
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Altor BioScience (part of ImmunityBio, Inc.) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Change in drug product development strategy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States — 139 open to participants now, 254 under way, 19 of them phase 3. Lymphoma, Non-Hodgkin · United States.

Enrollment
587th of 1,377
43 · median 35
Started
2015
with 41 others
Phase 1/2
205 of 1,599
22 open now
Registered
1,077th of 1,599
by date

Among the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, this one is the 587th largest by enrollment of the 1,377 interventional ones that give a count, is one of 42 that started in 2015, is one of 205 in phase 1/2, and was the 1,077th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

139 of the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States are open now. Recruiting first, the newest first:

134 more — sign in →

All 139 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, or all of them as a file.
02

Study summary

This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab.

Read the detailed description

The purpose of this study is to evaluate the safety and tolerability, identify the Maximum Tolerated Dose (MTD) or the Minimum Efficacious Dose (MED) and designate a dose level for Phase 2. Also characterize the immunogenicity, pharmacokinetic profile, and biomarker serum levels of N-803 in treated patients.

The effect of N-803 on the peripheral absolute lymphocyte counts and white blood cell counts, the number, phenotype and repertoire of peripheral blood T (total and subsets) and NK cells will be evaluated. In addition, a subset of patients will be evaluated for changes in lymph node immune composition. Anti-tumor responses and survival data will also be collected in this trial.

03

Conditions studied

  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma

Keywords

  • Lymphoma
  • indolent B Cell
  • non-Hodgkin Lymphoma
  • Cancer
  • Immunotherapy
  • Relapsed
  • Refractory
  • Rituximab
  • Interleukin-15
  • Absolute Lymphocyte Count
  • White Blood Cell
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Small Lymphocytic Lymphoma
  • Lymphoplasmacytic Lymphoma
  • anti-CD20
04

In context

Lymphoma, Non-Hodgkin Reclassified

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

This study's enrollment of 43 is close to the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.

Browse Lymphoma, Non-Hodgkin studies →

Lead sponsor

Altor BioScience is the lead sponsor of 15 studies on the registry; none are open to participants now.

First submitted before Altor BioScience became part of ImmunityBio, Inc..

Compared within Lymphoma, Non-Hodgkin, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • confirmed diagnosis of iNHL (Follicular lymphoma grade 1, 2, 3a; marginal zone lymphoma; small lymphocytic lymphoma or lymphoplasmacytic lymphoma) after treatment with at least 1 or more prior rituximab-containing regimens.

    • Anti-CD20 mAb- disease is defined as progressive disease while on rituximab (or another treatment of an anti-CD20 monoclonal antibody) or progression within 6 months of rituximab-containing (or another treatment of an anti-CD20 antibody-containing) therapy.
    • Anti-CD20 mAb-sensitive disease is defined by a response to a prior rituximab-containing (or another treatment of an anti-CD20 monoclonal antibody) regimen, and relapse more than 6 months from the last administration of rituximab-containing (or another treatment of an anti-CD20 antibody-containing) therapy.
  • :

    • At least one lymph node group ≥ 1.5 cm in longest transverse dimension. Patients with cutaneous only disease may be enrolled if they have a clearly measurable skin lesion.
    • Relapsed or Refractory iNHL that has progressed during or following 1 or more prior systemic rituximab-containing (or another treatment of an anti-CD20 antibody-containing) regimens for lymphoma

PRIOR/CONCURRENT THERAPY:

  • No anti-lymphoma treatments within 28 days before the start of study treatment.
  • Must have recovered from side effects of prior treatments.

PATIENT CHARACTERISTICS:

Performance Status

  • 0, 1, or 2

Renal Function • (GFR) > 40mL/min or Serum creatinine ≤ 1.5 X

Bone Marrow Reserve

  • ≥30,000/uL
  • ≥ 8g/dL
  • Absolute Lymphocytes ≥800/uL
  • ANC/AGC ≥750/uL

Hepatic Function

  • Total ≤ 2.0 X ULN (unless Gilbert's Syndrome or disease infiltration of liver is present)
  • , ALT ≤ 3.0 X ULN, or ≤ 5.0 X ULN (if liver lymphoma is present)
  • No positive Hep C serology or active Hep B infection

Cardiovascular

  • No congestive heart failure \< 6 months
  • No unstable angina pectoris \< 6 months
  • No myocardial infarction \< 6 months
  • No history of ventricular arrhythmias or severe cardiac dysfunction
  • No history of uncontrollable supraventricular arrhythmias
  • No Class > II CHF
  • No marked baseline prolongation of /QTc interval

Pulmonary

  • Normal clinical assessment of pulmonary function

Other

  • Negative serum pregnancy test if female and of
  • Women who are not pregnant or nursing
  • Subjects, both females and males, with must agree to use effective measures for the duration of the study
  • No known disease other than corrected hypothyroidism
  • No known prior organ allograft or transplantation
  • Not positive
  • No active CNS involvement with lymphoma
  • No psychiatric illness/social situation that would limit compliance
  • No other illness that in the opinion of the investigator would exclude the subject from participating in the study
  • Must provide and HIPPA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations
  • No active systemic infection requiring parenteral antibiotic therapy
  • No disease requiring systemic therapy (inhaled or topical are allowed). Adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.
  • No known histologic transformation from iNHL to DLBCL
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Phase 1 Cohort 1: N-803 - IV 1 ug/kg

    Biological: Rituximab · Biological: N-803

  • Experimental
    Phase 1 Cohort 2: N-803 - IV 3 ug/kg

    Biological: Rituximab · Biological: N-803

  • Experimental
    Phase 1 Cohort 3: N-803 - IV 6 ug/kg

    Biological: Rituximab · Biological: N-803

  • Experimental
    Phase 1 Cohort 4: N-803 - SQ 6 ug/kg

    Biological: Rituximab · Biological: N-803

  • Experimental
    Phase 1 Cohort 5: N-803 - SQ 10 ug/kg

    Biological: Rituximab · Biological: N-803

  • Experimental
    Phase 1 Cohort 6: N-803 - SQ 15 ug/kg

    Biological: Rituximab · Biological: N-803

  • Experimental
    Phase 1 Cohort 7: N-803 - SQ 20 ug/kg

    Biological: Rituximab · Biological: N-803

  • Experimental
    Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg

    Biological: Rituximab · Biological: N-803

  • Experimental
    Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg

    Biological: Rituximab · Biological: N-803

Interventions

  • BiologicalRituximab

    Intravenous infusion 375 mg/m\^2.

    Also known as: Rituxin

  • BiologicalN-803

    Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.

07

What researchers measure

Primary outcomes

  1. MTD or MED of N-803: IV 1, 3, 6 μg/kg, SQ 6, 10, 15, 20 μg/kg

    Maximum Tolerated Dose level (MTD) is defined as a dose level at which \<2 out of 6 patients experienced Dose Limiting Toxicity (DLT) and that is one level below a dose that was not tolerated. Minimal Efficacious Dose (MED) is defined as a dose level which produces an Absolute Lymphocyte Count (ALC) ≥25,000/μL sustained for 14 days or a total WBC ≥35,000/μL sustained for 14 days among 2/3 or 4/6 of patients. The elevated ALC cannot be attributed to circulating lymphoma cells. Dose levels for N-803 1, 3, 6 μg/kg IV, and 6, 10, 15, 20 μg/kg subcutaneous (SQ) were used to determine the MTD or MED.

    Time frame: 9 months

  2. Number of Participants With Treatment Emergent Adverse Events

    Treatment Emergent Adverse Event is defined as any AE that begins or worsens in grade after the start of study treatment until 30 days after the last dose of study treatment or end of study period, whichever is later.

    Time frame: 30 days after last dose, up to 40 weeks

  3. Overall Response Rate

    For Phase 1 and 2, overall response rate (ORR) will be calculated as the ratio of the number of patients who demonstrated response (CR+PR) divided by the number of patients in the Evaluable population. Response and disease progression criteria were defined by the 2007 IHP response assessments for malignant lymphoma.

    Time frame: 60 months

08

Results

Posted Jul 3, 2024

Participant flow

Phase 1
Participant flow — Phase 1
MilestonePhase 1 Cohort 1: N-803 - IV 1 ug/kgPhase 1 Cohort 2: N-803 - IV 3 ug/kgPhase 1 Cohort 3: N-803 - IV 6 ug/kgPhase 1 Cohort 4: N-803 - SQ 6 ug/kgPhase 1 Cohort 5: N-803 - SQ 10 ug/kgPhase 1 Cohort 6: N-803 - SQ 15 ug/kgPhase 1 Cohort 7: N-803 - SQ 20 ug/kgPhase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kgPhase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg
Started333333300
Completed131233300
Not completed202100000
Withdrew: Progressive disease201100000
Withdrew: Adverse event001000000
Phase 2
Participant flow — Phase 2
MilestonePhase 1 Cohort 1: N-803 - IV 1 ug/kgPhase 1 Cohort 2: N-803 - IV 3 ug/kgPhase 1 Cohort 3: N-803 - IV 6 ug/kgPhase 1 Cohort 4: N-803 - SQ 6 ug/kgPhase 1 Cohort 5: N-803 - SQ 10 ug/kgPhase 1 Cohort 6: N-803 - SQ 15 ug/kgPhase 1 Cohort 7: N-803 - SQ 20 ug/kgPhase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kgPhase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg
Started0000000169
Completed0000000136
Not completed000000033
Withdrew: Progressive disease000000012
Withdrew: Adverse event000000011
Withdrew: Failure to meet continuation criteria000000010

Outcome measures

PrimaryMTD or MED of N-803: IV 1, 3, 6 μg/kg, SQ 6, 10, 15, 20 μg/kg

Maximum Tolerated Dose level (MTD) is defined as a dose level at which \<2 out of 6 patients experienced Dose Limiting Toxicity (DLT) and that is one level below a dose that was not tolerated. Minimal Efficacious Dose (MED) is defined as a dose level which produces an Absolute Lymphocyte Count (ALC) ≥25,000/μL sustained for 14 days or a total WBC ≥35,000/μL sustained for 14 days among 2/3 or 4/6 of patients. The elevated ALC cannot be attributed to circulating lymphoma cells. Dose levels for N-803 1, 3, 6 μg/kg IV, and 6, 10, 15, 20 μg/kg subcutaneous (SQ) were used to determine the MTD or MED.

Time frame:
9 months
Reported as:
Number · SQ μg/kg
MTD or MED of N-803: IV 1, 3, 6 μg/kg, SQ 6, 10, 15, 20 μg/kg
SQ μg/kgPhase 1 Cohort 7: N-803 - SQ 20 μg/kg
MTD or MED of N-803: IV 1, 3, 6 μg/kg, SQ 6, 10, 15, 20 μg/kg20
PrimaryNumber of Participants With Treatment Emergent Adverse Events

Treatment Emergent Adverse Event is defined as any AE that begins or worsens in grade after the start of study treatment until 30 days after the last dose of study treatment or end of study period, whichever is later.

Time frame:
30 days after last dose, up to 40 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events
ParticipantsPhase 1 Cohort 1: N-803 - IV 1 ug/kgPhase 1 Cohort 2: N-803 - IV 3 ug/kgPhase 1 Cohort 3: N-803 - IV 6 ug/kgPhase 1 Cohort 4: N-803 - SQ 6 ug/kgPhase 1 Cohort 5: N-803 - SQ 10 ug/kgPhase 1 Cohort 6: N-803 - SQ 15 ug/kgPhase 1 Cohort 7: N-803 - SQ 20 ug/kgPhase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kgPhase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg
Phase 13333333——
Phase 2———————169
PrimaryOverall Response Rate

For Phase 1 and 2, overall response rate (ORR) will be calculated as the ratio of the number of patients who demonstrated response (CR+PR) divided by the number of patients in the Evaluable population. Response and disease progression criteria were defined by the 2007 IHP response assessments for malignant lymphoma.

Time frame:
60 months
Reported as:
Number · percentage of subjects
Overall Response Rate
percentage of subjectsPhase 1 Cohort 1: N-803 - IV 1 ug/kgPhase 1 Cohort 2: N-803 - IV 3 ug/kgPhase 1 Cohort 3: N-803 - IV 6 ug/kgPhase 1 Cohort 4: N-803 - SQ 6 ug/kgPhase 1 Cohort 5: N-803 - SQ 10 ug/kgPhase 1 Cohort 6: N-803 - SQ 15 ug/kgPhase 1 Cohort 7: N-803 - SQ 20 ug/kgPhase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kgPhase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg
Phase 133 (0.8 to 90.6)33 (0.8 to 90.6)67 (9.4 to 99.2)33 (0.8 to 90.6)67 (9.4 to 99.2)67 (9.4 to 99.2)100 (29.2 to 100)——
Phase 2———————80 (51.9 to 95.7)33 (7.5 to 70.1)

Adverse events

Collected over All AEs and SAEs were to be reported within 30 days of the last dose of study treatment, regardless of attribution, up to 40 weeks. All deaths were followed during the disease progression and survival follow-up period, up to 42 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1 Cohort 1: N-803 - IV 1 ug/kg0/3 (0%)0/3 (0%)3/3 (100%)
Phase 1 Cohort 2: N-803 - IV 3 ug/kg0/3 (0%)0/3 (0%)3/3 (100%)
Phase 1 Cohort 3: N-803 - IV 6 ug/kg0/3 (0%)1/3 (33.3%)3/3 (100%)
Phase 1 Cohort 4: N-803 - SQ 6 ug/kg0/3 (0%)1/3 (33.3%)3/3 (100%)
Phase 1 Cohort 5: N-803 - SQ 10 ug/kg0/3 (0%)0/3 (0%)3/3 (100%)
Phase 1 Cohort 6: N-803 - SQ 15 ug/kg0/3 (0%)0/3 (0%)3/3 (100%)
Phase 1 Cohort 7: N-803 - SQ 20 ug/kg0/3 (0%)1/3 (33.3%)3/3 (100%)
Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg0/16 (0%)3/16 (18.8%)16/16 (100%)
Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg0/9 (0%)2/9 (22.2%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventPhase 1 Cohort 1: N-803 - IV 1 ug/kgPhase 1 Cohort 2: N-803 - IV 3 ug/kgPhase 1 Cohort 3: N-803 - IV 6 ug/kgPhase 1 Cohort 4: N-803 - SQ 6 ug/kgPhase 1 Cohort 5: N-803 - SQ 10 ug/kgPhase 1 Cohort 6: N-803 - SQ 15 ug/kgPhase 1 Cohort 7: N-803 - SQ 20 ug/kgPhase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kgPhase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg
Small intestinal obstructionGastrointestinal disorders0/30/31/30/30/30/30/30/160/9
Cerebrovascular accidentNervous system disorders0/30/30/31/30/30/30/30/160/9
Urinary tract infectionInfections and infestations0/30/30/30/30/30/31/31/160/9
Pleural effusionRespiratory, thoracic and mediastinal disorders0/30/30/30/30/30/30/30/161/9
NeutropeniaBlood and lymphatic system disorders0/30/30/30/30/30/30/30/161/9
PyrexiaGeneral disorders0/30/30/30/30/30/30/30/161/9
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders0/30/30/30/30/30/30/31/160/9
Sinus node dysfunctionCardiac disorders0/30/30/30/30/30/30/31/160/9
AscitesGastrointestinal disorders0/30/30/30/30/30/30/31/160/9
Most frequent other events
Showing 10 of 150
Most frequent other events
EventPhase 1 Cohort 1: N-803 - IV 1 ug/kgPhase 1 Cohort 2: N-803 - IV 3 ug/kgPhase 1 Cohort 3: N-803 - IV 6 ug/kgPhase 1 Cohort 4: N-803 - SQ 6 ug/kgPhase 1 Cohort 5: N-803 - SQ 10 ug/kgPhase 1 Cohort 6: N-803 - SQ 15 ug/kgPhase 1 Cohort 7: N-803 - SQ 20 ug/kgPhase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kgPhase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg
NauseaGastrointestinal disorders2/32/33/32/30/31/31/34/160/9
VomitingGastrointestinal disorders1/32/33/31/30/31/30/30/160/9
ChillsGeneral disorders2/33/32/33/33/33/33/312/166/9
FatigueGeneral disorders1/32/33/31/31/33/33/37/166/9
Injection site reactionGeneral disorders0/30/30/33/33/33/33/313/168/9
PyrexiaGeneral disorders2/32/32/31/32/33/33/313/169/9
Abdominal painGastrointestinal disorders1/31/32/30/30/30/30/30/160/9
ConstipationGastrointestinal disorders0/31/31/31/31/32/31/32/162/9
DiarrhoeaGastrointestinal disorders0/30/31/31/31/31/32/33/161/9
Localised oedemaGeneral disorders0/30/30/30/30/32/31/31/160/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phase 1 Cohort 1: N-803 - IV 1 ug/kgPhase 1 Cohort 2: N-803 - IV 3 ug/kgPhase 1 Cohort 3: N-803 - IV 6 ug/kgPhase 1 Cohort 4: N-803 - SQ 6 ug/kgPhase 1 Cohort 5: N-803 - SQ 10 ug/kgPhase 1 Cohort 6: N-803 - SQ 15 ug/kgPhase 1 Cohort 7: N-803 - SQ 20 ug/kgPhase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kgPhase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kgTotal
Phase 158.0 ± 1.0064.7 ± 7.3769.3 ± 8.3960.0 ± 4.5865.0 ± 10.4468.3 ± 10.2162.0 ± 3.61——63.9 ± 7.28
Phase 2———————59.5 ± 11.3969.1 ± 12.5463.0 ± 12.48
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1 Cohort 1: N-803 - IV 1 ug/kgPhase 1 Cohort 2: N-803 - IV 3 ug/kgPhase 1 Cohort 3: N-803 - IV 6 ug/kgPhase 1 Cohort 4: N-803 - SQ 6 ug/kgPhase 1 Cohort 5: N-803 - SQ 10 ug/kgPhase 1 Cohort 6: N-803 - SQ 15 ug/kgPhase 1 Cohort 7: N-803 - SQ 20 ug/kgPhase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kgPhase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kgTotal
Phase 1 — Female2200223——11
Phase 1 — Male1133110——10
Phase 2 — Female———————10212
Phase 2 — Male———————6713
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1 Cohort 1: N-803 - IV 1 ug/kgPhase 1 Cohort 2: N-803 - IV 3 ug/kgPhase 1 Cohort 3: N-803 - IV 6 ug/kgPhase 1 Cohort 4: N-803 - SQ 6 ug/kgPhase 1 Cohort 5: N-803 - SQ 10 ug/kgPhase 1 Cohort 6: N-803 - SQ 15 ug/kgPhase 1 Cohort 7: N-803 - SQ 20 ug/kgPhase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kgPhase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kgTotal
Phase 1 — American Indian or Alaska Native0000000000
Phase 1 — Asian0000000000
Phase 1 — Native Hawaiian or Other Pacific Islander0000000000
Phase 1 — Black or African American0010000001
Phase 1 — White33233330020
Phase 1 — More than one race0000000000
Phase 1 — Unknown or Not Reported0000000000
Phase 2 — American Indian or Alaska Native———————000
Phase 2 — Asian———————022
Phase 2 — Native Hawaiian or Other Pacific Islander———————000
Phase 2 — Black or African American———————011
Phase 2 — White———————14620
Phase 2 — More than one race———————101
Phase 2 — Unknown or Not Reported———————101
Patients with relapse/refractory indolent B cell non-Hodgkin lymphoma
Patients with relapse/refractory indolent B cell non-Hodgkin lymphoma(Participants)Phase 1 Cohort 1: N-803 - IV 1 ug/kgPhase 1 Cohort 2: N-803 - IV 3 ug/kgPhase 1 Cohort 3: N-803 - IV 6 ug/kgPhase 1 Cohort 4: N-803 - SQ 6 ug/kgPhase 1 Cohort 5: N-803 - SQ 10 ug/kgPhase 1 Cohort 6: N-803 - SQ 15 ug/kgPhase 1 Cohort 7: N-803 - SQ 20 ug/kgPhase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kgPhase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kgTotal
Phase 13333333——21
Phase 2———————16925
09

Study locations

4 sites
  • University of Minnesota Cancer Center
    Minneapolis, Minnesota 55455, United States
  • Washington University School of Medicine Oncology
    St Louis, Missouri 63110, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
10

References and documents

Publications

  • Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA. Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clin Cancer Res. 2021 Jun 15;27(12):3339-3350. doi: 10.1158/1078-0432.CCR-20-4575. Epub 2021 Apr 8. PubMed 33832946 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Dec 2020, 67 months.

Results were first posted in Jul 2024, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2015
First posted
Mar 10, 2015
StartActual
Apr 17, 2015
Primary completionActual
Dec 13, 2020
CompletionActual
Dec 13, 2020
Results first posted
Jul 3, 2024
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02384954
Lead sponsor
Altor BioScience
Responsible party
Sponsor
First posted
Mar 10, 2015
Start date
Apr 17, 2015
Primary completion
Dec 13, 2020
Completion
Dec 13, 2020
Results posted
Jul 3, 2024
Last update
Jul 3, 2024

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nogapendekin alfa inbakicept

Start the discussion